Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

RNC Pharma Database Update: Pharmaceutical Drug Production in Russia (March 2018)

Wednesday, April 25, 2018

Between January and March 2018, Russia produced 75.7 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is 0.5% higher than that of the same period of 2017. In physical terms, it is around 1.01 bln units, which is 10% lower than that of the same period of 2017.

We can see the negative dynamics both for over-the-counter and Rx drugs, with the over-the-counter drug production having fallen by 12.6% over the year. While the production of Rx drugs showed positive dynamics in February, it decreased by 5.6% in March. Among the top 10 EphMRA groups of second level that are leaders in physical terms, seven showed negative dynamics in March 2018. The following groups showed tworst dynamics: antivirals (-36%), neuroleptics (-26%), cold and cough medications (-22%) and painkillers (-21%.) This is obviously due to a relatively low incidence of influenza and ARVI at the beginning of the year, which has had a big influence on the season’s trends.

Among the top 10 companies, Pharmstandard and Tatkhimfarmpreparaty still show the worst dynamics, with -26% and 22%, respectively. Pharmastandard has considerably decreased the production of the popular Citramon (-60%), Acidum Ascorbinicum (-38%), and Corvalolunm (-37%.) However, the production of the promoted Complivit and Pentalgin has also fallen by 32% and 26%, respectively. Tatkhimfarmpreparaty has decreased the production of Cough Pills (-80%), Ortophenum (-41%), and Validol (-35%.)

However, Pharmstandard has increased its production of Naphthyzin (by 4 times) and Pancreatinum (by 3.6 times), while Tatkhimfarmpreparaty has increased the production of Liquid Paraffin (by 3.5 times) and Ehrithromicin (by 3.3 times).

Read more about pharmaceutical drug production in Russia (February results) here: http://rncph.com/news/26_03_2018

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – March 2018)

Share: